RU2018133818A - Способы лечения заболеваний, характеризующихся вазоконстрикцией - Google Patents
Способы лечения заболеваний, характеризующихся вазоконстрикцией Download PDFInfo
- Publication number
- RU2018133818A RU2018133818A RU2018133818A RU2018133818A RU2018133818A RU 2018133818 A RU2018133818 A RU 2018133818A RU 2018133818 A RU2018133818 A RU 2018133818A RU 2018133818 A RU2018133818 A RU 2018133818A RU 2018133818 A RU2018133818 A RU 2018133818A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- use according
- disease
- disorder
- vasoconstriction
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 19
- 201000010099 disease Diseases 0.000 title claims 10
- 150000001875 compounds Chemical class 0.000 claims 15
- 208000035475 disorder Diseases 0.000 claims 9
- 206010047139 Vasoconstriction Diseases 0.000 claims 7
- 238000011282 treatment Methods 0.000 claims 7
- 230000025033 vasoconstriction Effects 0.000 claims 7
- 206010061218 Inflammation Diseases 0.000 claims 3
- 101710096361 Prostaglandin E synthase Proteins 0.000 claims 3
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 3
- 206010039710 Scleroderma Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- 206010056340 Diabetic ulcer Diseases 0.000 claims 2
- 208000003782 Raynaud disease Diseases 0.000 claims 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1603311.0 | 2016-02-25 | ||
| GBGB1603311.0A GB201603311D0 (en) | 2016-02-25 | 2016-02-25 | New uses and methods |
| PCT/GB2017/050498 WO2017144909A1 (en) | 2016-02-25 | 2017-02-24 | Methods of treating diseases characterised by vasoconstriction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018133818A true RU2018133818A (ru) | 2020-03-25 |
| RU2018133818A3 RU2018133818A3 (enExample) | 2020-05-27 |
Family
ID=55806947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018133818A RU2018133818A (ru) | 2016-02-25 | 2017-02-24 | Способы лечения заболеваний, характеризующихся вазоконстрикцией |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190038603A1 (enExample) |
| EP (1) | EP3419620A1 (enExample) |
| JP (1) | JP2019510079A (enExample) |
| CN (1) | CN109069487A (enExample) |
| AU (1) | AU2017222406B2 (enExample) |
| CA (1) | CA3014728A1 (enExample) |
| GB (1) | GB201603311D0 (enExample) |
| RU (1) | RU2018133818A (enExample) |
| WO (1) | WO2017144909A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111417394B (zh) | 2017-10-19 | 2023-11-07 | 帝人制药株式会社 | 苯并咪唑衍生物及其用途 |
| WO2020097396A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| US12509455B2 (en) | 2018-11-07 | 2025-12-30 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof |
| CA3156828A1 (en) | 2019-10-03 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Tricyclic kinase inhibitors and uses thereof |
| WO2021096314A1 (ko) * | 2019-11-15 | 2021-05-20 | 가천대학교 산학협력단 | 신규한 벤즈이미다졸 유도체 및 이의 용도 |
| TW202204350A (zh) | 2020-05-06 | 2022-02-01 | 美商雅捷可斯治療公司 | 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| EP4267574B1 (en) | 2020-12-23 | 2025-04-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
| TW202345806A (zh) | 2022-03-31 | 2023-12-01 | 美商艾伯維有限公司 | 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑 |
| TW202409037A (zh) * | 2022-07-06 | 2024-03-01 | 日商Ａｓｋａ製藥股份有限公司 | 嘧啶衍生物 |
| GB202212749D0 (en) | 2022-09-01 | 2022-10-19 | Gesynta Pharma Ab | New uses |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2207547A4 (en) * | 2007-10-05 | 2010-11-17 | Amira Pharmaceuticals Inc | PROTEIN INHIBITORS THAT ACTIVATE 5-LIPOXYGENASE |
| UY32470A (es) * | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| WO2011023812A1 (en) * | 2009-08-27 | 2011-03-03 | Novasaid Ab | Microsomal prostaglandin e synthase-1 (mpges1) inhibitors |
| US8759537B2 (en) * | 2010-08-20 | 2014-06-24 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
| EP2495244A1 (en) * | 2011-03-02 | 2012-09-05 | NovaSaid AB | Piperidinyl benzoimidazole derivatives as mPGEs-1 inhibitors |
| ES2561105T3 (es) * | 2011-08-18 | 2016-02-24 | Nippon Shinyaku Co., Ltd. | Derivado heterocíclico como inhibidor de prostaglandina E sintasa microsómica (mPGES) |
| TWI651310B (zh) * | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
| KR20160134865A (ko) * | 2014-04-14 | 2016-11-23 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | 아미드 유도체 및 이의 약제학적으로 허용되는 염, 이의 제조방법 및 이의 의학적 적용 |
-
2016
- 2016-02-25 GB GBGB1603311.0A patent/GB201603311D0/en not_active Ceased
-
2017
- 2017-02-24 EP EP17713372.5A patent/EP3419620A1/en not_active Withdrawn
- 2017-02-24 US US16/079,203 patent/US20190038603A1/en not_active Abandoned
- 2017-02-24 JP JP2018563946A patent/JP2019510079A/ja active Pending
- 2017-02-24 AU AU2017222406A patent/AU2017222406B2/en not_active Ceased
- 2017-02-24 RU RU2018133818A patent/RU2018133818A/ru unknown
- 2017-02-24 WO PCT/GB2017/050498 patent/WO2017144909A1/en not_active Ceased
- 2017-02-24 CN CN201780012516.XA patent/CN109069487A/zh active Pending
- 2017-02-24 CA CA3014728A patent/CA3014728A1/en active Pending
-
2022
- 2022-01-05 US US17/569,049 patent/US20220218670A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| GB201603311D0 (en) | 2016-04-13 |
| AU2017222406B2 (en) | 2022-06-02 |
| JP2019510079A (ja) | 2019-04-11 |
| AU2017222406A1 (en) | 2018-08-30 |
| EP3419620A1 (en) | 2019-01-02 |
| US20220218670A1 (en) | 2022-07-14 |
| WO2017144909A1 (en) | 2017-08-31 |
| CA3014728A1 (en) | 2017-08-31 |
| CN109069487A (zh) | 2018-12-21 |
| US20190038603A1 (en) | 2019-02-07 |
| RU2018133818A3 (enExample) | 2020-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019510079A5 (enExample) | ||
| PE20191474A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer | |
| EA201790088A1 (ru) | Ингибиторы syk | |
| CR20170563A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
| CY1120836T1 (el) | Ενωσεις 1,3,4-θειαδιαζοαης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| JP2016518437A5 (enExample) | ||
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| EA201792235A1 (ru) | Инъецируемые препараты замедленного высвобождения, содержащие изоксазолиновое действующее вещество, способы и применение | |
| JP2015504091A5 (enExample) | ||
| CR20180253A (es) | Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana | |
| CL2015002606A1 (es) | Compuesto. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| HK1211290A1 (en) | Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases | |
| MX2016010328A (es) | Tratamiento con halogeno de ataque cardiaco y lesion isquemica. | |
| JP2016522254A5 (enExample) | ||
| CL2018001830A1 (es) | Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida | |
| EA201591649A1 (ru) | Составы с органическими соединениями | |
| MX2021003150A (es) | Agentes monomericos y multimericos contra el vhb. | |
| HK1247837A1 (zh) | 1-甲基-d-色氨酸的盐和前药 | |
| AR108712A1 (es) | (5r)-5-[3-[(3s)-4-(4-cloro-3-metoxi-5-metil-fenil)-3-metil-piperazin-1-il]-3-oxo-propil]-5-metil-imidazolidin-2,4-diona, composiciones farmacéuticas del mismo para el tratamiento de trastornos inflamatorios y osteoartritis | |
| BR112023025552A2 (pt) | Composições estabilizadas de apilimod e usos das mesmas | |
| MX392555B (es) | Composiciones y métodos para el tratamiento de resistencia a la insulina. | |
| RU2016103098A (ru) | Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii |